ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Flagship Pioneering, Inc.
The Principal Scientist will lead analytical development for novel lipid nanoparticles (LNPs) and nucleic acid cargos, driving method development, characterization, and control strategies from platform research through IND. The role partners with formulation, process development, and translational teams, manages external lab/CRO relationships, and supervises junior scientists while maintaining hands-on experimental involvement. This position supports establishing CQAs/CPPs and contributes to technical documentation and regulatory-ready analytical strategies.
Headquarters
Cambridge, Massachusetts, United States
Company Size
201-500 employees
Founded
2000
Flagship Pioneering is a venture creation and investment firm that invents, builds, and funds early-stage companies in biotechnology, life sciences, and sustainability. Using an integrated model of in-house science, lab infrastructure, capital, and operational support, it spins out and scales breakthrough ventures — it has helped found more than 100 companies, including high-profile names such as Moderna. Flagship focuses on deep‑science innovation and long‑term partnerships to translate novel discoveries into transformative products for human health and the planet.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Flagship Pioneering, Inc..
individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week
Jul 20, 2025
Scientist, Drug Product Analytical
NewLimit
Scientist
Serif
Senior/Research Associate, Drug Product Development
NewLimit
Associate Scientist - Product Biochemistry (siRNA Therapeutics, Lipid Nanoparticles)
Regeneron Pharmaceuticals
RAII – SRA, Analytical Development
nChroma Bio
Director/Senior Director, CMC Operations
Beam Therapeutics
